NCPE sets a conditional reimbursement path for perioperative pembrolizumab in resectable NSCLC
On 10 March 2026, the National Centre for Pharmacoeconomics recommended perioperative pembrolizumab in resectable high-risk NSCLC be considered for reimbursement if cost-effectiveness improves, citing strong direct trial evidence versus chemotherapy and uncertain indirect comparative estimates versus nivolumab-based care.
Fatigue NMA publication surge sharpens outcome-construct governance requirements for HTA submissions
A rapid March 2026 rise in newly indexed network meta-analyses across fatigue, bipolar depression, and rheumatoid arthritis highlights an execution gap for evidence teams: turning fast-moving comparative evidence into dossier-grade outputs requires explicit endpoint, comparator, and time-window governance.
FDA approves dupilumab efficacy supplement for allergic fungal rhinosinusitis with AIMS trial basis
FDA approved a priority efficacy supplement for dupilumab in allergic fungal rhinosinusitis on 23 February 2026, with the AIMS randomized trial and label-embedded endpoint evidence supporting the decision context.
Cochrane pilots responsible AI tools — abstract screening, full-text review, and NMA — using the RAISE framework for evidence synthesis. A new governance baseline for systematic reviewers and HTA teams.
https://www.mattheneus.com/editorial/cochrane-ai-synthesis-march2026 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
Cochrane Pilots Responsible AI Tools in Evidence Synthesis
Cochrane has selected AI tools for its evidence synthesis platform study using the Responsible AI Standards in Evidence Synthesis (RAISE) framework, covering abstract screening, full-text screening, and data extraction phases.
Cross-domain NMA transitivity stress-testing: a March 2026 playbook for decision teams
Recent PubMed network meta-analysis publications across pharmacotherapy, surgery, and procedure-plus-medication pathways show why decision teams need explicit transitivity stress tests before converting rank outputs into reimbursement narratives.
Model-based treatment-duration NMA is becoming submission-critical: a governance playbook for evidence teams
New March 2026 publications show model-based duration-response network meta-analysis moving into practical evidence-generation workflows, requiring earlier protocol governance and tighter clinical-economic assumption alignment.
Outcome-measurement heterogeneity is now a first-order ITC and NMA submission risk
A 15 March 2026 meta-analytic review reports rising outcome-measurement heterogeneity and measurable treatment-estimate shifts across depression psychotherapy trials. For HTA teams, the immediate operational response is endpoint governance by design: protocol-level mapping rules, instrument-stratified sensitivity plans, and audit-traceable assumption control across ITC, MAIC, and NMA workflows.
SMC accepts Alyftrek for restricted NHSScotland use, with evidence lineage anchored in active-comparator CFTR-modulator studies
On 9 March 2026, SMC accepted vanzacaftor/tezacaftor/deutivacaftor for restricted use in NHSScotland for people aged 6 years and older with at least one F508del mutation, with clinical lineage drawn from European Medicines Agency direct comparative study evidence.
SMC submission-route mix in March 2026 signals a four-lane evidence architecture for faster HTA readiness
SMC records published on 9 March 2026 show mixed submission routes in one cycle, highlighting the need for route-specific evidence operations that align clinical, economic, and timeline controls before filing.
Anchored Comparator Governance Is Back: What This Week of ITC and NMA Publications Means for Evidence Teams
Recent PubMed indexed evidence synthesis publications show a renewed emphasis on anchored comparator design and transparent assumptions. This article translates that seven day signal into a concrete governance playbook for HTA facing evidence teams.
AbangeLabs